(Supplementary information)

Enzyme/pH-Sensitive nanoparticles based on Poly (β-L-malic acid) for drug delivery with enhanced endocytosis

Songyan Guo^{a,b*}, Youbei Qiao^b, Chaoli Wang^b, Yuming Zhang^a, TieHong Yang^b and

Hong Wu^{b*}

^a Department of Scientific Research, Shaanxi Provincial People's Hospital, Youyi West

Street NO.256, Xi'an 710068, People's Republic of China.

^b Department of Pharmaceutical Analysis, School of Pharmacy, Air Force Medical

University, 169 West Changle Street, Xi'an 710032, People's Republic of China.

Correspondent author: Songyan Guo and Hong Wu.

E-mail addresses: spphgsy@126.com (Songyan Guo), hongwuxa@163.com (Hong Wu).



Scheme. S1 Synthesized of CAD and CAD-ETA



Scheme. S2 Synthesized of PBM



Scheme. S3 Synthesized of PPC



Scheme. S4 Synthesized of PAPC



Scheme. S5 Synthesized of PPTC



Fig. S1 The GPC chromatography of PMLA.



Fig. S2 FTIR (A), ¹H NMR (400 MHz) (B) and MS(C) spectrum of CAD



Fig. S3 ¹H-NMR (400 MHz) (A) and FTIR(B) spectrum of PEG-AANL-PMLA-CAD(PAPC)



Fig. S4 ¹H-NMR (400 MHz) (A) and FTIR (B) spectrum of TAT-PEG-PMLA-CAD (PPTC)



Fig. S5 ¹H-NMR (400 MHz) (A) and FTIR(B) spectrum of PEG-PMLA-CAD(PPC)



Fig. S6 The zeta potential of different DOX-loaded nanomaterials

Table. S1 Summary of size, Zeta-potential, PDI, and DOX drug content of EP-NPs, P-NPs, E-NPs and C-NPs.

Nanoparticles	Size	PDI*	Zeta-potential	DOX content
	(nm)		(mV)	(wt.%)
EP-NPs	129.7±3.5	0.19	-17.63 ± 1.06	25.3
P-NPs	116.9 ± 2.6	0.12	-16.89 ± 0.63	24.2
E-NPs	143.1 ± 3.2	0.19	-16.65 ± 1.51	21.6
C-NPs	132.0±4.2	0.17	-15.89 ± 1.15	24.1

*PDI: Polydispersity Index.

Table. S2 Summary of IC50 value of Free DOX, EP-NPs, P-NPs, E-NPs and C-NPsagainst MDA-MB-231 cells and L929.

	MDA-MB-231 (µg/mL)		L929 (µg/mL)	
	IC50 (pH 7.4)	IC50 (pH 6.3)	IC50 (pH 7.4)	IC50 (pH 6.3)
Free-DOX	0.92	0.96	1.22	1.31
EP-NPs	27.52	1.08	31.22	9.12
P-NPs	27.43	4.03	33.54	9.97
E-NPs	27.99	17.24	36.21	10.16
C-NPs	29.15	19.13	34.11	16.22